Thanks to the rapid development of Covid-19 vaccines, nearly two-thirds of patient advocacy groups believe the pharmaceutical industry was effective at tackling the pandemic, boosting its reputation last year to the highest level in a decade. But at the same time, a majority of the groups also found that, besides research and development, drug makers were lacking in most other areas of operation.
Specifically, 62% of the groups believed the industry, as a whole, dealt effectively with the coronavirus. For this reason, half of the groups feel that drug companies now have an excellent or good reputation, according to the survey by PatientView, a research firm that canvassed 1,920 groups from 84 countries between November 2020 and February 2021. They rated the reputations of 48 drug makers.
In fact, for the first time in five years, a solid majority of the groups indicated that drug makers were good or excellent at innovation and producing medicines that benefit patients, 57% and 59%, respectively. A number of the groups also commented that they wished the industry could duplicate those same skills in the future for medicines used to treat other conditions.
About the Author Reprints
